Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants have announced the first surgeries in Australia using the company’s proprietary Endoskeleton interbody fusion devices and surface technology, marking the company’s entry into a robust new market.
The first two ALIF cases were performed successfully in October by Richard Laherty, pictured, spine surgeon at Queensland Neurosurgery and Spine Surgery at the Princess Alexandra Hospital near Brisbane.
Laherty commented: “I have been keeping up on the studies Titan Spine has published on their proprietary surface technologies over the years that have consistently shown the ability to create a superior osteogenic environment over other materials and surfaces. I was pleased to finally have the opportunity to use the Endoskeleton titanium devices featuring Titan’s unique surface technology at the macro, micro and cellular level for these procedures. In the first few weeks following these initial cases, we have observed favourable patient outcomes in both cases, and I look forward to offering the Endoskeleton devices to more of my patients moving forward.”
Titan Spine received registration approval from the Australian Therapeutic Goods Administration (TGA) in June 2014 to commercially market its full line of Endoskeleton interbody fusion devices in the country.
